|
2025
|
P/S
|
Providing health information; Providing a web site featuring medical information |
|
2024
|
P/S
|
Providing health information; patient support services relating to the treatment of postpartum de... |
|
|
P/S
|
Pharmaceutical preparations. |
|
|
P/S
|
Pharmaceutical preparations |
|
|
P/S
|
Pharmaceutical preparations |
|
|
Invention
|
Neuroactive steroid formulations and methods of use thereof. Described herein are pharmaceutical ... |
|
|
Invention
|
Lymphatic system-targeting compounds. The disclosure provides lymphatic system-targeting compound... |
|
|
P/S
|
Pharmaceutical preparations. Providing health and medical information about diseases, disorders a... |
|
|
Invention
|
Neuroactive steroids and compositions thereof.
Provided herein is a compound of Formula (I):
P... |
|
|
Invention
|
Neuroactive steroids and their methods of use.
Provided herein is a compound of Formula (I) or a... |
|
|
Invention
|
Oxysterols and methods of use thereof.
Compounds are provided according to Formula (I): Formula ... |
|
|
Invention
|
Crystalline forms of a neuroactive steroid. This invention relates to crystalline forms of anhydr... |
|
|
Invention
|
Compositions and methods for treating cns disorders.
Described herein are neuroactive steroids o... |
|
|
Invention
|
C7 substituted oxysterols and methods of use thereof.
Compounds are provided according to Formul... |
|
|
P/S
|
Pharmaceutical preparations for use in the treatment of central nervous system diseases and disor... |
|
|
Invention
|
Neuroactive steroids and methods of use thereof.
3beta, 17beta disubstituted steroidal compounds... |
|
2023
|
Invention
|
Oxysterols and methods of use thereof.
Compounds are provided according to Formula (I), and phar... |
|
|
Invention
|
Oxysterols and methods of use thereof.
Compounds are provided according to Formula (III):
Comp... |
|
|
Invention
|
Negative nmda-modulating compounds and methods of use thereof. Compounds are provided according t... |
|
|
Invention
|
Method of screening compounds for treating cns disorders.
Provided herein are screening methods ... |
|
|
Invention
|
Oxysterols and methods of use thereof.
Compounds are provided according to Formula (I):
Compou... |
|
|
P/S
|
House mark for pharmaceutical preparations Providing health and medical information about disease... |
|
|
Invention
|
Neuroactive steroids, compositions, and uses thereof.
Provided herein are 19-nor C3, 3-disubstit... |
|
|
Invention
|
Compounds for treating cns disorders.
Provided herein in part is a compound of Formula (I): or a... |
|
|
Invention
|
Deuterated neuroactive steroids. Provided herein is a deuterated compound of Formula (I) or a pha... |
|
|
Invention
|
Crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid.
This invention relates to a cryst... |
|
|
Invention
|
Neuroactive steroids, compositions and uses thereof.
Described herein are steroids of Formula (I... |
|
|
Invention
|
Crystalline forms of a neuroactive steroid. This invention relates to crystalline solvated forms ... |
|
|
Invention
|
Neuroactive steroids, compositions, and uses thereof.
Described herein are neuroactive steroids ... |
|
|
Invention
|
Oxysterols and methods of use thereof.
Compounds are provided according to Formula (I) and pharm... |
|
|
Invention
|
Crystalline form of a neuroactive steroid. The disclosure relates to a crystalline solid form of ... |
|
|
Invention
|
Crystalline forms of a neuroactive steroid. The disclosure relates to Compound 1 and crystalline ... |
|
|
Invention
|
Neuroactive steroids and their methods of use. 55c is carbon-bound substituted or unsubstituted h... |
|
|
Invention
|
Compositions and methods for treating cns disorders.
Provided herein is a compound of Formula (I... |
|
|
Invention
|
Compositions and methods for treating cns disorders. Provided herein is a compound of Formula (I)... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, d... |
|
|
Invention
|
Oxysterols and methods of use thereof. 8 are as defined herein. Compounds of the present inventio... |
|
|
Invention
|
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of c... |
|
|
Invention
|
Oxysterols and methods of use thereof. G are as defined herein. Compounds of the present inventio... |
|
2022
|
Invention
|
Neuroactive steroid for the treatment of huntington's disease.
Provided herein are methods for i... |
|
|
Invention
|
Neuroactive steroids, compositions, and uses thereof.
Described herein are methods of treating a... |
|
|
Invention
|
Neuroactive steroids, compositions, and uses thereof. 3, A and L are as defined herein. Such comp... |
|
|
Invention
|
Deuterated positive nmda-modulating compounds and methods of use thereof.
Deuterated compounds a... |
|
|
Invention
|
Positive nmda-modulating compounds and methods of use thereof.
Compounds are provided according ... |
|
|
P/S
|
pharmaceutical preparations for the treatment of epilepsy, essential tremors, Parkinson's disease... |
|
|
Invention
|
Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's di... |
|
|
Invention
|
19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder ... |
|
|
Invention
|
Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a ... |
|
|
Invention
|
Treatment of essential tremor.
The present invention provides a method of treating essential tre... |
|
|
Invention
|
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorde... |
|
|
Invention
|
Use of neuroactive steroid for treatment of sexual dysfunction.
This invention relates to method... |
|
|
Invention
|
Use of neuroactive steroids for treatment of sexual dysfunction.
This invention relates to metho... |
|
2021
|
Invention
|
Use of gabaa modulators for treatment of respiratory conditions.
Provided herein are methods for... |
|
|
Invention
|
Use of agents for treatment of respiratory conditions.
Provided herein are methods for treating ... |
|
|
Invention
|
Neuroactive steroids and their methods of use.
Provided herein is a compound of Formula (I), or ... |
|
2020
|
P/S
|
House mark for pharmaceutical preparations |
|
|
P/S
|
Pharmaceutical products. |
|
|
P/S
|
Pharmaceutical products |
|
2019
|
P/S
|
Pharmaceutical preparations for the treatment of epilepsy, depression, Parkinson's disease, essen... |
|
|
P/S
|
house mark for pharmaceutical preparations |
|
|
P/S
|
Providing health and medical information about postpartum depression and treatment; patient suppo... |
|
2018
|
P/S
|
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; p... |
|
|
P/S
|
Providing information in the fields of health, medicine, and pharmaceuticals related to depression |
|
|
P/S
|
Pharmaceutical preparations for the diagnosis and treatment of central nervous system disorders, ... |
|
2017
|
P/S
|
pharmaceutical preparations |
|
|
P/S
|
pharmaceutical preparations for the treatment of postpartum depression |
|
|
P/S
|
Prescription pharmaceutical preparations for the treatment of epilepsy, depression and postpartum... |
